^
Association details:
| Biomarker: | FGFR2 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | nintedanib (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer (NSCLC) (NCT02299141).
Published date:
05/28/2020
Excerpt:
...patients with advanced non-small cell lung cancer (NSCLC) with mutations in TP53, VEGFR1-3, PDGFR-A, PDGFR-B, and FGFR1-3 treated with nintedanib...The ORR was 15% with 3/20 partial responses (PR), while 12 patients had stable disease (SD), with disease control (PR+SD≥16 weeks) rate of 60% (12/20). The median progression-free survival and median overall survival were 18 weeks (95% CI: 8-31) and 48 weeks (95% CI:15-56) respectively...nintedanib showed modest activity.
DOI:
10.1200/JCO.2020.38.15_suppl.e21694
Trial ID:
